BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 11776372)

  • 21. Endosomal translocation of CpG-oligodeoxynucleotides inhibits DNA-PKcs-dependent IL-10 production in macrophages.
    Yotsumoto S; Saegusa K; Aramaki Y
    J Immunol; 2008 Jan; 180(2):809-16. PubMed ID: 18178819
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen.
    Davis HL; Weeratna R; Waldschmidt TJ; Tygrett L; Schorr J; Krieg AM
    J Immunol; 1998 Jan; 160(2):870-6. PubMed ID: 9551923
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Encapsulation in liposomal nanoparticles enhances the immunostimulatory, adjuvant and anti-tumor activity of subcutaneously administered CpG ODN.
    de Jong S; Chikh G; Sekirov L; Raney S; Semple S; Klimuk S; Yuan N; Hope M; Cullis P; Tam Y
    Cancer Immunol Immunother; 2007 Aug; 56(8):1251-64. PubMed ID: 17242927
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity.
    Chu RS; Targoni OS; Krieg AM; Lehmann PV; Harding CV
    J Exp Med; 1997 Nov; 186(10):1623-31. PubMed ID: 9362523
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effective induction of CD8+ T-cell response using CpG oligodeoxynucleotides and HER-2/neu-derived peptide co-encapsulated in liposomes.
    Li WM; Dragowska WH; Bally MB; Schutze-Redelmeier MP
    Vaccine; 2003 Jul; 21(23):3319-29. PubMed ID: 12804863
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeted liposomal delivery of TLR9 ligands activates spontaneous antitumor immunity in an autochthonous cancer model.
    Hamzah J; Altin JG; Herringson T; Parish CR; Hämmerling GJ; O'Donoghue H; Ganss R
    J Immunol; 2009 Jul; 183(2):1091-8. PubMed ID: 19561111
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeting of immunostimulatory DNA cures experimental visceral leishmaniasis through nitric oxide up-regulation and T cell activation.
    Datta N; Mukherjee S; Das L; Das PK
    Eur J Immunol; 2003 Jun; 33(6):1508-18. PubMed ID: 12778468
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CpG oligodeoxynucleotides stimulate protective innate immunity against pulmonary Klebsiella infection.
    Deng JC; Moore TA; Newstead MW; Zeng X; Krieg AM; Standiford TJ
    J Immunol; 2004 Oct; 173(8):5148-55. PubMed ID: 15470059
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antimetastatic effect of CpG DNA mediated by type I IFN.
    Hafner M; Zawatzky R; Hirtreiter C; Buurman WA; Echtenacher B; Hehlgans T; Männel DN
    Cancer Res; 2001 Jul; 61(14):5523-8. PubMed ID: 11454702
    [TBL] [Abstract][Full Text] [Related]  

  • 30. G3139 and other CpG-containing immunostimulatory phosphorothioate oligodeoxynucleotides are potent suppressors of the growth of human tumor xenografts in nude mice.
    Gekeler V; Gimmnich P; Hofmann HP; Grebe C; Römmele M; Leja A; Baudler M; Benimetskaya L; Gonser B; Pieles U; Maier T; Wagner T; Sanders K; Beck JF; Hanauer G; Stein CA
    Oligonucleotides; 2006; 16(1):83-93. PubMed ID: 16584297
    [TBL] [Abstract][Full Text] [Related]  

  • 31. TLR9-dependent systemic interferon-beta production by intravenous injection of plasmid DNA/cationic liposome complex in mice.
    Yoshida H; Nishikawa M; Yasuda S; Mizuno Y; Toyota H; Kiyota T; Takahashi R; Takakura Y
    J Gene Med; 2009 Aug; 11(8):708-17. PubMed ID: 19462411
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Structure-efficacy relationships of immunostimulatory activity of CpG-containing oligodeoxynucleotides on mouse spleen cells.
    Du HY; Xia SY; Song HF; Li N; Shang MM; Zou J; Wang QQ; Ou L; Sun X; Ji AG; Tang ZM
    Acta Pharmacol Sin; 2007 Oct; 28(10):1637-44. PubMed ID: 17883951
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CpG motifs as proinflammatory factors render autochthonous tumors permissive for infiltration and destruction.
    Garbi N; Arnold B; Gordon S; Hämmerling GJ; Ganss R
    J Immunol; 2004 May; 172(10):5861-9. PubMed ID: 15128765
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Both E7 and CpG-oligodeoxynucleotide are required for protective immunity against challenge with human papillomavirus 16 (E6/E7) immortalized tumor cells: involvement of CD4+ and CD8+ T cells in protection.
    Kim TY; Myoung HJ; Kim JH; Moon IS; Kim TG; Ahn WS; Sin JI
    Cancer Res; 2002 Dec; 62(24):7234-40. PubMed ID: 12499264
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Synergistic activation of innate immunity by double-stranded RNA and CpG DNA promotes enhanced antitumor activity.
    Whitmore MM; DeVeer MJ; Edling A; Oates RK; Simons B; Lindner D; Williams BR
    Cancer Res; 2004 Aug; 64(16):5850-60. PubMed ID: 15313929
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CpG motifs of bacterial DNA exacerbate colitis of dextran sulfate sodium-treated mice.
    Obermeier F; Dunger N; Deml L; Herfarth H; Schölmerich J; Falk W
    Eur J Immunol; 2002 Jul; 32(7):2084-92. PubMed ID: 12115630
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Contribution of plasmid DNA to inflammation in the lung after administration of cationic lipid:pDNA complexes.
    Yew NS; Wang KX; Przybylska M; Bagley RG; Stedman M; Marshall J; Scheule RK; Cheng SH
    Hum Gene Ther; 1999 Jan; 10(2):223-34. PubMed ID: 10022547
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Novel immunostimulatory phosphodiester oligodeoxynucleotides with CpT sequences instead of CpG motifs.
    Kim D; Jung J; Lee Y; Kwon HJ
    Mol Immunol; 2011 Jul; 48(12-13):1494-504. PubMed ID: 21529949
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CpG ODN 2006 and IL-12 are comparable for priming Th1 lymphocyte and IgG responses in cattle immunized with a rickettsial outer membrane protein in alum.
    Zhang Y; Palmer GH; Abbott JR; Howard CJ; Hope JC; Brown WC
    Vaccine; 2003 Jul; 21(23):3307-18. PubMed ID: 12804862
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Significant antitumor effects obtained by autologous tumor cell vaccine engineered to secrete interleukin (IL)-12 and IL-18 by means of the EBV/lipoplex.
    Asada H; Kishida T; Hirai H; Satoh E; Ohashi S; Takeuchi M; Kubo T; Kita M; Iwakura Y; Imanishi J; Mazda O
    Mol Ther; 2002 May; 5(5 Pt 1):609-16. PubMed ID: 11991752
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.